26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be a good buy,  and the full calculations will raise questions about NICE methods.

Pfizer and BioNTech have announced the early results of their COVID-19 vaccine trial, and immunisation for the novel coronavirus could be available in months. Of course hurdles remain, and more data need to be gathered about the efficacy and safety of the vaccines being trialled. 

One hurdle that new health technologies usually have to jump is cost effectiveness: is the value of the benefits worth the costs?

Read BMJ article